Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BOLTNASDAQ:CRISNASDAQ:SABSNASDAQ:SGYP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBOLTBolt Biotherapeutics$0.35+0.7%$0.39$0.30▼$1.34$13.55M0.96173,379 shs23,213 shsCRISCuris$2.41-2.8%$2.09$1.02▼$16.93$20.46M3.5166,987 shs128,628 shsSABSSAB Biotherapeutics$1.60-5.9%$1.48$1.00▼$5.01$14.86M0.5262,637 shs46,928 shsSGYPSynergy Pharmaceuticals$0.02$0.03▼$2.23$7.44M4.946.08 million shsN/AA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBOLTBolt Biotherapeutics+0.71%-9.36%-11.85%-27.86%-68.44%CRISCuris-2.82%+47.85%+62.84%-31.53%-84.93%SABSSAB Biotherapeutics-6.49%-8.57%+28.00%-26.94%-61.35%SGYPSynergy Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBOLTBolt Biotherapeutics2.533 of 5 stars3.03.00.00.00.83.31.3CRISCuris2.602 of 5 stars3.53.00.00.02.90.01.3SABSSAB Biotherapeutics3.263 of 5 stars3.55.00.00.01.91.71.3SGYPSynergy PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBOLTBolt Biotherapeutics 2.00Hold$1.13218.25% UpsideCRISCuris 3.00Buy$21.00771.37% UpsideSABSSAB Biotherapeutics 3.00Buy$11.40612.50% UpsideSGYPSynergy Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SGYP, SABS, CRIS, and BOLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $20.004/1/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.003/31/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.003/25/2025BOLTBolt BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/25/2025BOLTBolt BiotherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$1.50 ➝ $1.25(Data available from 5/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBOLTBolt Biotherapeutics$7.69M1.76N/AN/A$2.97 per share0.12CRISCuris$10.91M1.88N/AN/A$3.34 per share0.72SABSSAB Biotherapeutics$2.24M6.64N/AN/A$6.21 per share0.26SGYPSynergy Pharmaceuticals$16.82M0.00N/AN/A($0.02) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBOLTBolt Biotherapeutics-$69.20M-$1.66N/AN/AN/A-665.56%-69.46%-48.55%5/13/2025 (Estimated)CRISCuris-$47.41M-$7.03N/AN/AN/A-443.35%-923.37%-78.35%5/6/2025 (Estimated)SABSSAB Biotherapeutics-$42.19M-$3.68N/AN/AN/A-1,450.14%-94.37%-67.26%5/19/2025 (Estimated)SGYPSynergy Pharmaceuticals-$224.33M-$1.02N/AN/AN/A-332.11%N/A-118.14%N/ALatest SGYP, SABS, CRIS, and BOLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025SABSSAB Biotherapeutics-$1.00N/AN/AN/A$0.13 millionN/A5/13/2025Q1 2025BOLTBolt Biotherapeutics-$0.34N/AN/AN/A$0.77 millionN/A5/6/2025Q1 2025CRISCuris-$1.39N/AN/AN/A$2.37 millionN/A3/31/2025Q4 2024CRISCuris-$1.36-$1.25+$0.11-$1.25$2.04 million$2.70 million3/28/2025Q4 2024SABSSAB Biotherapeutics-$1.16-$1.23-$0.07-$1.23$0.12 million$0.05 million3/24/2025Q4 2024BOLTBolt Biotherapeutics-$0.38-$0.38N/A-$0.42$0.79 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBOLTBolt Biotherapeutics$0.36101.84%N/AN/A N/ACRISCurisN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ASGYPSynergy PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBOLTBolt Biotherapeutics0.213.163.16CRISCurisN/A1.221.22SABSSAB Biotherapeutics0.093.693.69SGYPSynergy PharmaceuticalsN/A0.520.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBOLTBolt Biotherapeutics86.70%CRISCuris29.97%SABSSAB Biotherapeutics7.82%SGYPSynergy Pharmaceuticals28.47%Insider OwnershipCompanyInsider OwnershipBOLTBolt Biotherapeutics30.90%CRISCuris5.45%SABSSAB Biotherapeutics26.46%SGYPSynergy Pharmaceuticals4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBOLTBolt Biotherapeutics9038.34 million26.45 millionNot OptionableCRISCuris608.49 million7.98 millionNo DataSABSSAB Biotherapeutics1409.29 million6.79 millionNot OptionableSGYPSynergy PharmaceuticalsN/A248.04 millionN/AOptionableSGYP, SABS, CRIS, and BOLT HeadlinesRecent News About These CompaniesStrong Buy Rating for Syndax Pharmaceuticals Driven by Promising Pipeline and Solid FinancialsNovember 6, 2024 | markets.businessinsider.comGen Z: The untapped audienceOctober 19, 2024 | pharmaphorum.comSynergy PharmaceuticalsAugust 9, 2024 | thepharmaletter.comJose SolorioApril 12, 2024 | seekingalpha.comSynergy starts construction on one of Australia’s biggest batteriesMarch 19, 2024 | power-technology.comPYC Therapeutics and Google Cloud partner for new precision medicinesJanuary 2, 2024 | msn.comSynergy Pharma Investors Win Revival of Suit Over Stock DilutionAugust 28, 2023 | news.bloomberglaw.comAvia Solutions Group acquires UK airline Synergy AviationJuly 17, 2023 | stattimes.comDental Association Calls for Synergy Between Public, Private PracticesJune 15, 2023 | thisdaylive.comSynergy Pharmaceuticals Inc Unit (SGYPU)May 9, 2023 | investing.comMarket Factor Synergy Signals Exciting Growth For Digital PathologyApril 12, 2023 | forbes.comHPCL signs pact with BPCL for hydrogen synergyApril 4, 2023 | auto.economictimes.indiatimes.comDifferent resistorsMarch 29, 2023 | bbc.co.ukMains cablesMarch 28, 2023 | bbc.co.ukEnergy changes in brakingMarch 28, 2023 | bbc.co.ukBlues plans launch Synergie to cut costs for the priciest drugsJanuary 8, 2023 | modernhealthcare.comSynergy Pharmaceuticals (SGYP) Stock Higher in After-Hours Trading Following Paulson InvestmentDecember 18, 2022 | thestreet.comJiangxi Synergy Pharmaceutical Co Ltd (300636)September 13, 2022 | investing.comi-Synergy’s Ledger Labs provides software development in blockchain and AI to businessJuly 25, 2022 | stockhead.com.auSyros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q1 2022 Results - Earnings Call TranscriptMay 16, 2022 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSGYP, SABS, CRIS, and BOLT Company DescriptionsBolt Biotherapeutics NASDAQ:BOLT$0.35 +0.00 (+0.71%) Closing price 05/2/2025 03:48 PM EasternExtended Trading$0.35 -0.01 (-2.12%) As of 05/2/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.Curis NASDAQ:CRIS$2.41 -0.07 (-2.82%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$2.44 +0.02 (+1.04%) As of 05/2/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.SAB Biotherapeutics NASDAQ:SABS$1.60 -0.10 (-5.88%) Closing price 05/2/2025 03:58 PM EasternExtended Trading$1.60 0.00 (0.00%) As of 05/2/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.Synergy Pharmaceuticals NASDAQ:SGYPSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 04/28 - 05/02 Amazon Earnings: 2 Reasons to Love It, 1 Reason to Be Cautious Meta Takes A Bow With Q1 Earnings - Watch For Tariff Impact in Q2 Why Spotify Stock Still Has Room to Run in 2025 Is It Time to Load Up on Bond ETFs? Palantir Earnings: 1 Bullish Signal and 1 Area of Concern Roblox Stock Gains Momentum and Can Top $100 in 2025 Visa Q2 Earnings Top Forecasts, Adds $30B Buyback Plan Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
